^
    Back
    Association details:
    Biomarker:TMB-H + PD-L1 expression
    Cancer:Urothelial Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2020
    Title:

    Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.

    Published date:
    05/13/2020
    Excerpt:
    PD-L1 IC2/3 was associated with significantly longer OS for atezo mono vs placebo + PBC and a combination of PD-L1 IC2/3, and high TMB (> 10 muts/Mb) identified a pt subset (ā‰ˆ 14% of BEP) with particularly favorable outcomes with atezo mono vs placebo + PBC; similar results for PD-L1 and TMB were not seen with atezo + PBC vs placebo + PBC.
    DOI:
    10.1200/JCO.2020.38.15_suppl.5011
    Trial ID:
    IMvigor130
    Test:
    FoundationOneĀ® CDx, VENTANA PD-L1 (SP142) Assay